



2019 NOMINEE BIOSKETCH FORM

NAME	Lucinda Billingham
PRESENT POSITION	Professor of Biostatistics and Director of Biostatistics for Cancer Research UK Clinical Trials Unit at University of Birmingham
DEGREES	BSc Mathematics, MSc Applied Statistics, PhD Medical Statistics
MAIN RESEARCH INTERESTS	<ol style="list-style-type: none"> 1. Application of Bayesian methods in clinical trials 2. Design and analysis of practice-changing trials in rare diseases 3. Early phase clinical trial design 4. Statistical methodology for evaluation of stratified medicine 5. Methodology for simultaneous analysis of quality of life & survival
SELECTED PUBLICATIONS IN CLINICAL BIostatISTICS (LIMIT TO 5)	<ol style="list-style-type: none"> 1. Brock K, Billingham L, et al; Implementing the EffTox dose-finding design in the Matchpoint trial. <i>BioMed Central Medical Research Methodology</i> 2017; 17(1): 112. 2. Yap C, Billingham L, et al; Dose Transition Pathways: The missing link between complex dose-finding designs and simple decision-making. <i>Clinical Cancer Research</i> 2017; 23(24): 7440-7. 3. Ferry D, Billingham L et al; Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial (BTOG2). <i>European Journal of Cancer</i> 2017; 83: 302-312. 4. Billingham LJ, Malottki K, Steven N; Research methodology to influence clinical practice for patients with rare cancers; <i>Lancet Oncology</i> 2016: 17(2) e70-80. 5. Malottki K, Popat S, Deeks JJ, Riley RD, Nicholson AG, Billingham L; Problems of variable biomarker evaluation in stratified medicine research – a case study of ERCC1 in non-small cell lung cancer; <i>Lung Cancer</i> 2016; 92: 1-7.
PAST AND CURRENT PARTICIPATION IN ISCB ACTIVITIES	<p>I have been a member of the ISCB for the last 25 years and attended every annual conference, regularly presenting contributed papers and posters, chairing sessions and this year providing a pre-conference course. In 2011, I was a member of the Scientific Programme Committee for the annual conference in Ottawa. In 2016 we hosted the 37th ISCB Conference in Birmingham for which I was Chair of the Local Organising Committee and member of Scientific Programme Committee. I was an elected member of the ISCB Executive Committee during 2008 –2012, also serving on Sub-Committees for Membership and Conference Organising.</p>
GOALS AND VISION FOR THE ISCB	<p>I am great advocate of the ISCB, as demonstrated by my continued contribution to the activities of the society over the last 25 years. I believe it provides an essential forum for dissemination and discussion of methodology for biostatisticians working in all areas of clinical research. For me, the annual conference has been a major inspiration and influence on my role as an applied biostatistician working in a world-class clinical trials unit.</p> <p>I would welcome the opportunity to provide leadership for the ISCB and ensure the ongoing success of the society. In particular, future conferences should continue to stimulate relevant research both in terms of novel methods and application. As an integral member of the international biostatistics community, including my current membership on the Council of the Royal Statistical Society, I would foster effective collaborations with relevant societies. In my opinion, one of the most important roles of the ISCB is it's relevance to clinical medicine. With my extensive experience in collaborating internationally with clinicians and patient groups, I would strive to expand the recognition and influence of ISCB on these important partners.</p>